Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance
Lilly's Q1 2026 revenue surged 56% to $19.8 billion, driven by strong volume growth despite lower prices for Mounjaro and Zepbound.
Asset / Drug
Drug and asset intelligence for Mounjaro with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.